Craft

CytomX Therapeutics

Stock Price

$1.3

2024-07-04

Market Capitalization

$101.3 M

2024-07-04

Revenue

$101.2 M

FY, 2023

CytomX Therapeutics Summary

Company Summary

Overview
CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics. The Company's Probody Platform allows to design drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation. This ability to localize therapeutic effects to the tumor reduces systemic toxicity, with potential for safer and more effective therapies for a broad array of validated and previously inaccessible oncology targets. Driven by a vision to transform patient lives, CytomX is an advancing multiple Probody cancer immunotherapies and Probody drug conjugates toward clinical investigation, while also applying its technology to bispecific T-cell engaging antibodies and ProCAR-NK cell therapies.
Type
Public
Status
Active
Founded
2008
HQ
South San Francisco, CA, US | view all locations
Website
http://cytomx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Sean A. McCarthy

    Sean A. McCarthy, Chief Executive Officer and Chairman

  • Jeff Landau

    Jeff Landau, SVP, Head of Strategy and Chief Business Officer

  • Leslie Robbins

    Leslie Robbins, SVP, Intellectual Property

Operating MetricsView all

Phase I Trials Products

1

FY, 2016

Pre-Clinical Phase Products

4

FY, 2016

Patents (US)

13

FY, 2016

LocationsView all

1 location detected

  • South San Francisco, CA HQ

    United States

    151 Oyster Point Blvd #400

CytomX Therapeutics Financials

Summary Financials

Revenue (Q1, 2024)
$41.5M
Net income (Q1, 2024)
$13.8M
Cash (Q1, 2024)
$36.2M
EBIT (Q1, 2024)
$11.7M
Enterprise value
$78.0M

Footer menu